Disease · MONDO_0006727

diastolic heart failure

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diastolic heart failure. Diseases, record MONDO_0006727. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006727

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diastolic heart failure; Open Targets
Open Targets ID: MONDO_0006727; Open Targets
Other names: Heart Failure, Diastolic; Open Targets
Disease Ontology: DOID:9775; Disease Ontology
MeSH: D054144; MeSH
Highest stage of its drugs: Phase 3, for 2 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EXENATIDE	CHEMBL414357	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SILDENAFIL	CHEMBL192	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALAGEBRIUM	CHEMBL2111081	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ALAGEBRIUM CHLORIDE	CHEMBL2107309	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IVABRADINE	CHEMBL471737	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NESIRITIDE	CHEMBL1201668	Protein	Phase 1/2	ClinicalTrials.gov	3	3	3	Drugs and targets
SAPROPTERIN	CHEMBL1201774	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
EPLERENONE	CHEMBL1095097	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GLP1R	Glucagon-like peptide 1 receptor	1	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
HCN4	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	1	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker	Phase 2	https://conductscience.org/library/genes/10021	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Unknown	https://conductscience.org/library/genes/3156	Drugs and targets
NPR1	Atrial natriuretic peptide receptor 1	1	Atrial natriuretic peptide receptor A agonist	Phase 1/2	https://conductscience.org/library/genes/4881	Drugs and targets
NR3C2	Mineralocorticoid receptor	1	Mineralocorticoid receptor antagonist	Unknown	https://conductscience.org/library/genes/4306	Drugs and targets
PAH	Phenylalanine-4-hydroxylase	1	Phenylalanine-4-hydroxylase activator	Early phase 1	https://conductscience.org/library/genes/5053	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	1	Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00763867	Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)	Phase 3	216	2013-07-03	Heart Failure	SILDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT00387621	Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction	Phase 1/2	58	2012-05-17	Congestive Heart Failure	NESIRITIDE	Its record names the disease	ClinicalTrials.gov
NCT02251431	Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome	Phase 3	57	2023-05-17	Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction	EXENATIDE	Its record names the disease	ClinicalTrials.gov
NCT00585611	Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients	Not applicable	1	2019-03-26	Diastolic Heart Failure	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00662116	Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)	Phase 2	160		Diastolic Heart Failure	ALAGEBRIUM	Its record names the disease	ClinicalTrials.gov
NCT00516646	The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure	Phase 2	100		Heart Failure	ALAGEBRIUM	Its record names the disease	ClinicalTrials.gov
NCT00302250	The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension	Phase 2	70		Cardiovascular Disease	ALAGEBRIUM, ALAGEBRIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00505336	The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure	Not applicable	43		Diastolic Heart Failure	ATORVASTATIN, EPLERENONE	Its record names the disease	ClinicalTrials.gov
NCT00208780	Effects of Tetrahydrobiopterin on Blood Pressure	Early phase 1	24		Hypertension	SAPROPTERIN	Its record names the disease	ClinicalTrials.gov
NCT00043836	The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure	Phase 2	20		Heart Failure, Congestive, Dyspnea, Pulmonary Edema	ALAGEBRIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sildenafil vs Placebo: serious adverse events	25 of 113	16 of 103	216	NCT00763867	Trial comparisons
Nesiritide vs Placebo: serious adverse events	1 of 58	0 of 58	116	NCT00387621	Trial comparisons
Exenatide-extended Release vs Placebo: deaths from any cause	0 of 29	0 of 28	57	NCT02251431	Trial comparisons
Exenatide-extended Release vs Placebo: serious adverse events	0 of 29	1 of 28	57	NCT02251431	Trial comparisons

Papers from its trials17

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23478662	RESULT	1	PubMed
18322548	RESULT	1	PubMed
38533961	DERIVED	1	PubMed
35358904	DERIVED	1	PubMed
32150314	DERIVED	1	PubMed
31805424	DERIVED	1	PubMed
31272568	DERIVED	1	PubMed
28214792	DERIVED	1	PubMed
28194841	DERIVED	1	PubMed
27072860	DERIVED	1	PubMed

1 to 10 of 17

See all 17 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006727

GET https://conductscience.org/api/diseases/v1/MONDO_0006727/drugs

API reference For AI assistants